Published in World J Cardiol on April 26, 2013
Adipose tissue and vascular inflammation in coronary artery disease. World J Cardiol (2014) 0.84
Epicardial Fat: Physiological, Pathological, and Therapeutic Implications. Cardiol Res Pract (2016) 0.79
Thermogenic potential and physiological relevance of human epicardial adipose tissue. Int J Obes Suppl (2015) 0.75
Inflammation in atherosclerosis. Nature (2002) 28.92
Lessons from sudden coronary death: a comprehensive morphological classification scheme for atherosclerotic lesions. Arterioscler Thromb Vasc Biol (2000) 14.59
A prospective natural-history study of coronary atherosclerosis. N Engl J Med (2011) 10.66
Hemodynamic shear stress and its role in atherosclerosis. JAMA (1999) 9.27
Human epicardial adipose tissue is a source of inflammatory mediators. Circulation (2003) 6.31
Pericardial fat, visceral abdominal fat, cardiovascular disease risk factors, and vascular calcification in a community-based sample: the Framingham Heart Study. Circulation (2008) 5.95
Computed tomographic angiography characteristics of atherosclerotic plaques subsequently resulting in acute coronary syndrome. J Am Coll Cardiol (2009) 5.70
Echocardiographic epicardial adipose tissue is related to anthropometric and clinical parameters of metabolic syndrome: a new indicator of cardiovascular risk. J Clin Endocrinol Metab (2003) 4.05
Human epicardial adipose tissue: a review. Am Heart J (2007) 3.74
Epicardial adipose tissue: anatomic, biomolecular and clinical relationships with the heart. Nat Clin Pract Cardiovasc Med (2005) 3.38
Multislice computed tomographic characteristics of coronary lesions in acute coronary syndromes. J Am Coll Cardiol (2007) 2.97
Extent and direction of arterial remodeling in stable versus unstable coronary syndromes : an intravascular ultrasound study. Circulation (2000) 2.76
Evidence for increased collagenolysis by interstitial collagenases-1 and -3 in vulnerable human atheromatous plaques. Circulation (1999) 2.73
Anatomic properties of myocardial bridge predisposing to myocardial infarction. Circulation (2009) 2.48
Morphological predictors of arterial remodeling in coronary atherosclerosis. Circulation (2002) 2.39
Frequency and distribution of thin-cap fibroatheroma and ruptured plaques in human coronary arteries: a pathologic study. J Am Coll Cardiol (2007) 2.28
World Heart Day 2002: the international burden of cardiovascular disease: responding to the emerging global epidemic. Circulation (2002) 2.02
Adipose tissue in the mammalian heart and pericardium: structure, foetal development and biochemical properties. Comp Biochem Physiol B (1989) 1.93
Epicardial adipose tissue and insulin resistance in obese subjects. J Clin Endocrinol Metab (2005) 1.80
Epicardial adipose tissue and coronary artery plaque characteristics. Atherosclerosis (2009) 1.77
Adipocytokines and proinflammatory mediators from abdominal and epicardial adipose tissue in patients with coronary artery disease. Int J Obes (Lond) (2007) 1.67
Relation of epicardial adipose tissue to coronary atherosclerosis. Am J Cardiol (2008) 1.65
Epicardial adipose tissue: emerging physiological, pathophysiological and clinical features. Trends Endocrinol Metab (2011) 1.60
Epicardial fat: properties, function and relationship to obesity. Obes Rev (2007) 1.58
Threshold values of high-risk echocardiographic epicardial fat thickness. Obesity (Silver Spring) (2008) 1.54
The double role of epicardial adipose tissue as pro- and anti-inflammatory organ. Horm Metab Res (2008) 1.43
The ventricular epicardial fat is related to the myocardial mass in normal, ischemic and hypertrophic hearts. Cardiovasc Pathol (2004) 1.40
Plaque characteristics of thin-cap fibroatheroma evaluated by OCT and IVUS. JACC Cardiovasc Imaging (2011) 1.37
Epicardial fat: from the biomolecular aspects to the clinical practice. Int J Biochem Cell Biol (2011) 1.29
Site-specific properties of pericardial and epicardial adipose tissue: the effects of insulin and high-fat feeding on lipogenesis and the incorporation of fatty acids in vitro. Int J Obes (1990) 1.27
Epicardial adipose tissue as new cardio-metabolic risk marker and potential therapeutic target in the metabolic syndrome. Curr Pharm Des (2007) 1.14
Absence of atherosclerosis evolution in the coronary arterial segment covered by myocardial tissue in cholesterol-fed rabbits. Virchows Arch (1997) 1.09
Fas is expressed in human atherosclerotic intima and promotes apoptosis of cytokine-primed human vascular smooth muscle cells. Arterioscler Thromb Vasc Biol (1997) 1.09
Epicardial fat tissue thickness correlates with endothelial dysfunction and other cardiovascular risk factors in patients with metabolic syndrome. Metab Syndr Relat Disord (2010) 1.06
Enhanced inflammation in epicardial fat in patients with coronary artery disease. Int Heart J (2011) 1.05
Human epicardial adipokine messenger RNAs: comparisons of their expression in substernal, subcutaneous, and omental fat. Metabolism (2010) 1.03
Association of inflammation of the left anterior descending coronary artery with cardiovascular risk factors, plaque burden and pericardial fat volume: a PET/CT study. Eur J Nucl Med Mol Imaging (2010) 1.02
How to interpret epicardial adipose tissue as a cause of coronary artery disease: a meta-analysis. Coron Artery Dis (2012) 1.02
Increased epicardial fat tissue is a marker of metabolic syndrome in adult patients. Int J Cardiol (2011) 1.00
Pericardial rather than epicardial fat is a cardiometabolic risk marker: an MRI vs echo study. J Am Soc Echocardiogr (2011) 0.97
OCT assessment of thin-cap fibroatheroma distribution in native coronary arteries. JACC Cardiovasc Imaging (2010) 0.95
Pericardial fat and echocardiographic measures of cardiac abnormalities: the Jackson Heart Study. Diabetes Care (2011) 0.94
Coronary artery disease is associated with higher epicardial retinol-binding protein 4 (RBP4) and lower glucose transporter (GLUT) 4 levels in epicardial and subcutaneous adipose tissue. Clin Endocrinol (Oxf) (2012) 0.89
Epicardial adipose tissue: an emerging role for the development of coronary atherosclerosis. Clin Cardiol (2011) 0.86
Lower epicardial adipose tissue adiponectin in patients with metabolic syndrome. Cytokine (2011) 0.86
The impact of epicardial fat volume on coronary plaque vulnerability: insight from optical coherence tomography analysis. Eur Heart J Cardiovasc Imaging (2012) 0.85
Significance of the anatomical properties of a myocardial bridge in coronary heart disease. Circ J (2011) 0.85
Apoptosis in human atherosclerotic plaques. Apoptosis (1999) 0.81
New morphological insights on coronary plaque rupture: bridging the gap from anatomy to clinical presentation? JACC Cardiovasc Interv (2011) 0.79
Noninvasive detection of vulnerable plaques: are we there yet? J Am Coll Cardiol (2010) 0.77
Morphological characteristics of culprit coronary lesions according to clinical presentation: insights from a multimodality imaging approach. Int J Cardiovasc Imaging (2012) 0.77
Drug-eluting stent thrombosis: results from a pooled analysis including 10 randomized studies. J Am Coll Cardiol (2005) 3.17
Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives. J Am Coll Cardiol (2007) 2.73
Revascularisation versus medical treatment in patients with stable coronary artery disease: network meta-analysis. BMJ (2014) 2.62
Assessment of microcirculatory remodeling with intracoronary flow velocity and pressure measurements: validation with endomyocardial sampling in cardiac allografts. Circulation (2009) 2.23
Everolimus-eluting stent versus bare-metal stent in ST-segment elevation myocardial infarction (EXAMINATION): 1 year results of a randomised controlled trial. Lancet (2012) 2.14
Drug-eluting stent thrombosis: results from the multicenter Spanish registry ESTROFA (Estudio ESpañol sobre TROmbosis de stents FArmacoactivos). J Am Coll Cardiol (2008) 2.11
Subacute thrombosis of a bioresorbable vascular scaffold implanted for recurrent in-stent restenosis. EuroIntervention (2015) 1.98
Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease. J Am Coll Cardiol (2007) 1.94
Insulin therapy is associated with platelet dysfunction in patients with type 2 diabetes mellitus on dual oral antiplatelet treatment. J Am Coll Cardiol (2006) 1.94
Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment. Diabetes (2005) 1.88
Contribution of gene sequence variations of the hepatic cytochrome P450 3A4 enzyme to variability in individual responsiveness to clopidogrel. Arterioscler Thromb Vasc Biol (2006) 1.84
Background, incidence, and predictors of antiplatelet therapy discontinuation during the first year after drug-eluting stent implantation. Circulation (2010) 1.78
High clopidogrel loading dose during coronary stenting: effects on drug response and interindividual variability. Eur Heart J (2004) 1.77
Platelet aggregation according to body mass index in patients undergoing coronary stenting: should clopidogrel loading-dose be weight adjusted? J Invasive Cardiol (2004) 1.75
2014 ESC/EACTS guidelines on myocardial revascularization. Rev Esp Cardiol (Engl Ed) (2015) 1.69
Disturbed coronary hemodynamics in vessels with intermediate stenoses evaluated with fractional flow reserve: a combined analysis of epicardial and microcirculatory involvement in ischemic heart disease. Circulation (2013) 1.55
Prognostic impact of a chronic occlusion in a noninfarct vessel in patients with acute myocardial infarction and multivessel disease undergoing primary percutaneous coronary intervention. J Invasive Cardiol (2006) 1.54
Coronary stenting versus balloon angioplasty in small vessels: a meta-analysis from 11 randomized studies. J Am Coll Cardiol (2004) 1.53
The role of European national journals in education. Heart (2009) 1.46
LDL-cholesterol predicts negative coronary artery remodelling in diabetic patients: an intravascular ultrasound study. Eur Heart J (2005) 1.45
Effects of the acyl coenzyme A:cholesterol acyltransferase inhibitor avasimibe on human atherosclerotic lesions. Circulation (2004) 1.45
Is a 300 mg clopidogrel loading dose sufficient to inhibit platelet function early after coronary stenting? A platelet function profile study. J Invasive Cardiol (2004) 1.43
Effects of Triple Therapy in Patients With Non-Valvular Atrial Fibrillation Undergoing Percutaneous Coronary Intervention Regarding Thromboembolic Risk Stratification. Circ J (2015) 1.40
Expert review document part 2: methodology, terminology and clinical applications of optical coherence tomography for the assessment of interventional procedures. Eur Heart J (2012) 1.38
Randomized comparison of sirolimus-eluting stent versus standard stent for percutaneous coronary revascularization in diabetic patients: the diabetes and sirolimus-eluting stent (DIABETES) trial. Circulation (2005) 1.38
Meta-analysis comparing the effect of drug-eluting versus bare metal stents on risk of acute myocardial infarction during follow-up. Am J Cardiol (2007) 1.38
[Assessment of dynamic coronary plaque changes and the clinical consequences in type-II diabetic patients: a serial intracoronary ultrasound study]. Rev Esp Cardiol (2011) 1.37
Percutaneous intervention of a thrombotic-occluded saphenous vein graft successfully treated using the undersized stent approach to prevent distal embolization. Catheter Cardiovasc Interv (2011) 1.37
Morphometric assessment of coronary stenosis relevance with optical coherence tomography: a comparison with fractional flow reserve and intravascular ultrasound. J Am Coll Cardiol (2012) 1.29
Clopidogrel withdrawal is associated with proinflammatory and prothrombotic effects in patients with diabetes and coronary artery disease. Diabetes (2006) 1.27
[European National Society cardiovascular journals. Background, rationale and mission statement of the "editors' club"]. Rev Esp Cardiol (2008) 1.26
Identification of low responders to a 300-mg clopidogrel loading dose in patients undergoing coronary stenting. Thromb Res (2005) 1.17
Importance of diastolic fractional flow reserve and dobutamine challenge in physiologic assessment of myocardial bridging. J Am Coll Cardiol (2003) 1.16
Double antiplatelet therapy after drug-eluting stent implantation: risk associated with discontinuation within the first year. J Am Coll Cardiol (2012) 1.16
Combined use of OCT and IVUS in spontaneous coronary artery dissection. JACC Cardiovasc Imaging (2013) 1.09
2014 ESC/EACTS guidelines on myocardial revascularization. EuroIntervention (2015) 1.08
Fibromuscular dysplasia and spontaneous coronary artery dissection: coincidental association or causality? JACC Cardiovasc Interv (2013) 1.08
Lack of association between the P2Y12 receptor gene polymorphism and platelet response to clopidogrel in patients with coronary artery disease. Thromb Res (2005) 1.07
The optimal cutoff value for left main minimal lumen area of 4.5 mm(2): a word of caution. JACC Cardiovasc Interv (2015) 1.07
Calcified nodule mimicking red thrombus on optical coherence tomography. JACC Cardiovasc Interv (2015) 1.07
[Duplicate or redundant publication: can we afford it?]. Rev Esp Cardiol (2005) 1.06
Intracoronary brachytherapy after stenting de novo lesions in diabetic patients: results of a randomized intravascular ultrasound study. J Am Coll Cardiol (2004) 1.06
Impact of chronic kidney disease on platelet function profiles in diabetes mellitus patients with coronary artery disease taking dual antiplatelet therapy. J Am Coll Cardiol (2010) 1.05
Iatrogenic dissection of the ascending aorta following heart catheterisation: incidence, management and outcome. EuroIntervention (2006) 1.05
Thoracic Endovascular Aortic Repair (TEVAR) for the treatment of aortic diseases: a position statement from the European Association for Cardio-Thoracic Surgery (EACTS) and the European Society of Cardiology (ESC), in collaboration with the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur J Cardiothorac Surg (2012) 1.04
Spontaneous coronary artery dissection: new insights from the tip of the iceberg? Circulation (2012) 1.00
Efficacy and safety of drug-eluting stents in chronic total coronary occlusion recanalization: a systematic review and meta-analysis. J Am Coll Cardiol (2010) 0.99
Safety of lone thrombus aspiration without concomitant coronary stenting in selected patients with acute myocardial infarction. EuroIntervention (2013) 0.99
New insights on stent thrombosis: in praise of large nationwide registries for rare cardiovascular events. JACC Cardiovasc Interv (2012) 0.97
Treatment of drug-eluting stent restenosis the new pilgrimage: quo vadis? J Am Coll Cardiol (2010) 0.97
Paclitaxel-eluting balloons for small-vessel disease. J Am Coll Cardiol (2013) 0.96
Platelet function testing and cardiovascular outcomes: steps forward in identifying the best predictive measure. Thromb Haemost (2007) 0.96
Primary stenting in acute myocardial infarction secondary to right coronary artery dissection following blunt chest trauma. Usefulness of intracoronary ultrasound. Int J Cardiol (2005) 0.96
Influence of aspirin resistance on platelet function profiles in patients on long-term aspirin and clopidogrel after percutaneous coronary intervention. Am J Cardiol (2005) 0.95
Vascular effects of sirolimus-eluting versus bare-metal stents in diabetic patients: three-dimensional ultrasound results of the Diabetes and Sirolimus-Eluting Stent (DIABETES) Trial. J Am Coll Cardiol (2006) 0.95
Effectiveness of drug-eluting stents in patients with bare-metal in-stent restenosis: meta-analysis of randomized trials. J Am Coll Cardiol (2006) 0.94
Intravascular ultrasound findings during episodes of drug-eluting stent thrombosis. J Am Coll Cardiol (2007) 0.93
Prospective application of pre-defined intravascular ultrasound criteria for assessment of intermediate left main coronary artery lesions results from the multicenter LITRO study. J Am Coll Cardiol (2011) 0.92
Characterization of plaque prolapse after drug-eluting stent implantation in diabetic patients: a three-dimensional volumetric intravascular ultrasound outcome study. J Am Coll Cardiol (2006) 0.90
Very late mycotic pseudoaneurysm associated with drug-eluting stent fracture. Circulation (2012) 0.90
[Impactology, impactitis, impactotherapy]. Rev Esp Cardiol (2005) 0.89
Revascularization strategies in patients with diabetes. N Engl J Med (2013) 0.88
Low coronary microcirculatory resistance associated with profound hypotension during intravenous adenosine infusion: implications for the functional assessment of coronary stenoses. Circ Cardiovasc Interv (2014) 0.86
[New recommendations of the international committee of medical journal editors. Shifting focus: from uniformity in technical requirements to bioethical considerations]. Rev Esp Cardiol (2004) 0.86
Vessel shrinkage as a sign of atherosclerosis progression in type 2 diabetes: a serial intravascular ultrasound analysis. Diabetes (2008) 0.86
Digital enhancement of stent images in primary and secondary percutaneous coronary revascularisation. EuroIntervention (2009) 0.85
Primary percutaneous coronary intervention for ST-segment elevation acute myocardial infarction in nonagenarian patients: results from a Spanish multicentre registry. EuroIntervention (2011) 0.85
Clinical impact of in-stent late loss after drug-eluting coronary stent implantation. Eur Heart J (2007) 0.84
Multivessel intervention during primary angioplasty: too greedy? JACC Cardiovasc Interv (2010) 0.83
Lack of association between gene sequence variations of platelet membrane receptors and aspirin responsiveness detected by the PFA-100 system in patients with coronary artery disease. Platelets (2006) 0.83
[Summary of the clinical studies reported in the scientific session of the American Heart Association 2005 (Dallas, Texas, USA, 13-16 November 2005)]. Rev Esp Cardiol (2006) 0.83
[2014 ESC/EACTS Guidelines on myocardial revascularization]. Kardiol Pol (2014) 0.83
Greyscale intravascular ultrasound and IVUS-radiofrequency tissue characterisation to improve understanding of the mechanisms of coronary stent thrombosis in drug-eluting stents. EuroIntervention (2008) 0.82
Thrombosis of second-generation drug-eluting stents in real practice results from the multicenter Spanish registry ESTROFA-2 (Estudio Español Sobre Trombosis de Stents Farmacoactivos de Segunda Generacion-2). JACC Cardiovasc Interv (2010) 0.82
Intravascular ultrasound tissue characterization. I like the rainbow but...what's behind the colours? Eur Heart J (2008) 0.81
Cardiogenic shock at admission in patients with multivessel disease and acute myocardial infarction treated with percutaneous coronary intervention: related factors. Int J Cardiol (2007) 0.81
PlA polymorphism and platelet reactivity following clopidogrel loading dose in patients undergoing coronary stent implantation. Blood Coagul Fibrinolysis (2004) 0.81
Collagen embolization for the successful treatment of a distal coronary artery perforation. Catheter Cardiovasc Interv (2009) 0.81
Assessment of potential relationship between wall shear stress and arterial wall response after bare metal stent and sirolimus-eluting stent implantation in patients with diabetes mellitus. Int J Cardiovasc Imaging (2007) 0.81
Variability in platelet aggregation following sustained aspirin and clopidogrel treatment in patients with coronary heart disease and influence of the 807 C/T polymorphism of the glycoprotein Ia gene. Am J Cardiol (2005) 0.81
Sirolimus-eluting stent versus bare metal stent in diabetic patients: the final five-year follow-up of the DIABETES trial. EuroIntervention (2013) 0.81
Functional impact of high clopidogrel maintenance dosing in patients undergoing elective percutaneous coronary interventions. Results of a randomized study. Thromb Haemost (2008) 0.81
Evolutive recanalization of spontaneous coronary artery dissection: insights from a multimodality imaging approach. Circulation (2014) 0.81
Fractional flow reserve and minimum Pd/Pa ratio during intravenous adenosine infusion: very similar but not always the same. EuroIntervention (2016) 0.80
Long-term clinical benefit of sirolimus-eluting stent implantation in diabetic patients with de novo coronary stenoses: long-term results of the DIABETES trial. Eur Heart J (2007) 0.80
Diabetes mellitus and acute myocardial infarction: more data supporting a poorer microvasculature reperfusion. Am Heart J (2003) 0.80
Effectiveness of percutaneous coronary interventions in nonagenarians. Am J Cardiol (2004) 0.80
Prognostic implications of bundle branch block in patients undergoing primary coronary angioplasty in the stent era. Am J Cardiol (2010) 0.80
Findings of a mixed transfemoral aortic valve implantation program using Edwards and CoreValve devices. Rev Esp Cardiol (2010) 0.80
Clopidogrel-statin interaction: myth or reality? J Am Coll Cardiol (2007) 0.80
Transesophageal Doppler Analysis of Coronary Sinus Flow A New Method to Assess the Severity of Tricuspid Regurgitation. Echocardiography (1997) 0.79
Safety and efficacy of intense antithrombotic treatment and percutaneous coronary intervention deferral in patients with large intracoronary thrombus. Am J Cardiol (2013) 0.79
Proximal left anterior descending coronary artery revascularization with drug-eluting stents. Arq Bras Cardiol (2007) 0.79
Morphology of coronary artery lesions assessed by virtual histology intravascular ultrasound tissue characterization and fractional flow reserve. Int J Cardiovasc Imaging (2011) 0.79